Glimnib M1 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. This combination provides a complementary mechanism of action, making it effective for patients inadequately controlled on monotherapy. Glimnib M1 Forte Tablet PR is designed for prolonged release, ensuring sustained plasma concentration and improved patient compliance. It is prescribed as an adjunct to diet and exercise to achieve optimal glycemic targets. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is primarily associated with the glimepiride component. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Regular monitoring of blood glucose, renal function, and periodic assessment of vitamin B12 levels is recommended during therapy. This combination should be used under medical supervision to tailor dosing and minimize adverse effects, optimizing therapeutic outcomes in type 2 diabetes management.